Onc.AI is a digital health company focused on enhancing oncology decision-making through advanced artificial intelligence (AI) technologies. The company utilizes a comprehensive oncology real-world dataset that includes diagnostic imaging, electronic medical records (EMR), laboratory results, and genomic data. This rich dataset enables Onc.AI to develop a series of AI models aimed at optimizing precision oncology. Their initial product is designed to assist medical oncologists in making informed treatment decisions for patients with metastatic lung cancer who are undergoing PD-1 immunotherapy, thereby improving patient outcomes.

The company is committed to leveraging AI to transform cancer care, as evidenced by their recent achievements, including the development of the Serial Imaging Response Score, which has shown superior performance compared to traditional assessment methods for evaluating immunotherapy outcomes in non-small cell lung cancer (NSCLC). Onc.AI's innovative approach has garnered recognition and support, including a $2 million grant from the National Cancer Institute to further advance their AI-based clinical decision support systems. Through these initiatives, Onc.AI aims to provide clarity and precision in cancer treatment, ultimately enhancing the quality of care for patients.

United States

Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans.

Onc.AI

Company Details